Aurobindo Pharma receives USFDA approval for Raloxifene Hydrochloride tablets

31 Aug 2015 Evaluate

Aurobindo Pharma has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Raloxifene Hydrochloride Tablets USP 60mg (ANDA 204310). The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Evista Tablets, 60mg of Eli Lilly.

Raloxifene Hydrochloride Tablets are indicated for treatment and prevention of osteoporosis in postmenopausal women. The product has an estimated market size of $404 million for the twelve months ending June 2015.

This is the 45th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products. Aurobindo now has a total of 210 ANDA approvals (182 Final approvals including 9 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.


Aurobindo Pharma Share Price

1167.20 -5.10 (-0.44%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×